- Patients with newly diagnosed, histologically confirmed, metastatic non-squamous NSCLC whom: Have already received standard-of-care tissue genotyping using Next Generation Sequencing (NGS)for lung cancer at clinician's discretion, including at least EGFR, ALK, RET, ROS1, NTRK fusions,MET, BRAF, HER2 and KRAS, in the last 90 (ninety) calendar days of enrollment or Are scheduled to receive standard-of-care tissue genotyping using Next Generation Sequencing(NGS) for lung cancer at clinician's discretion, including at least EGFR, ALK, RET, ROS1, NTRKfusions, MET, BRAF, HER2 and KRAS
|
- Tissue genotyping is to be performed by Comprehensive Genomic Profiling (CGP) either in-house (atstudy site laboratory) or at an outside CAP-accredited laboratory by sending out tissue for analysis.Tissue CGP must be performed by Next Generation Sequencing (NGS). Other genomic platforms andmethodologies for tissue genomic profiling, such as PCR, FISH or IHC are not eligible for this study. Eligible subjects whose physician intends to order tissue for genotyping at study enrollment, but there isinsufficient material for analysis are still eligible for enrollment
|
- Patients with no previous surgical treatment, such as cancer resection, except patients with previouslyresected early stage NSCLC (stage I-IIIA), now with recurrent and metastatic disease, if tissue from asite of metastatic disease has been obtained within a 90 (ninety) calendar-day window of enrollment
|